Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$288MCash, Jun 2026
36moCash Runway (est.)
Follow EVMN by emailGet an email when EVMN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about EVMN, unsubscribe in one click. Privacy
📣 What EVMN Says Is Next
mid-2027 · “The Phase 2b dose-ranging study for EVO301 in moderate-to-severe AD, anticipated to begin in mid-2027, advances a core component of our broad inflammatory disease focused pipeline.” Late-Breaking Oral Presentation Title: Positive Top-line Data from the Phase 2a Proof-of-Concept Trial of EVO301, a Novel IL‑18 Binding Protein, in Patients with Moderate-to-Severe Atopic Dermatitis Session: D2T01.4 – Late Breaking News Presenter: Dr. Mark G.”
Company press release, Sep 23, 2026 · SEC filing
in 2027 · “Top-line data from the trial are expected in 2027.”
Company press release, Aug 6, 2026 · SEC filing
in 2027 · “Migraine Prophylaxis Phase 2b Trial Now Underway with Top-Line Data Anticipated in 2027: In July 2026 , the Company initiated a global randomized, double-blind, placebo-controlled Phase 2b dose-ranging clinical trial in migraine prophylaxis.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
EVMN reported $288M in cash and short-term investments (as of Jun 30, 2026) and used about $24.1M/quarter in operations, an estimated runway of 35.8 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EVMN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.